All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.
The aml Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the aml Hub cannot guarantee the accuracy of translated content. The aml and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.
The AML Hub is an independent medical education platform, sponsored by Daiichi Sankyo, Johnson & Johnson, Syndax, Thermo Fisher Scientific, Kura Oncology, AbbVie, and has been supported through an educational grant from the Hippocrate Conference Institute, an association of the Servier Group.
The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.
Now you can support HCPs in making informed decisions for their patients
Your contribution helps us continuously deliver expertly curated content to HCPs worldwide. You will also have the opportunity to make a content suggestion for consideration and receive updates on the impact contributions are making to our content.
Find out more
Create an account and access these new features:
Bookmark content to read later
Select your specific areas of interest
View AML content recommended for you
FDA accepts a supplemental new drug application for ruxolitinib in steroid-refractory cGvHD
On February 22, 2021, the U.S. Food and Drug Administration (FDA) granted priority review to a supplemental new drug application (sNDA) for ruxolitinib for the treatment of patients aged 12 years and older with steroid-refractory chronic graft-versus-host disease (cGvHD).1
Ruxolitinib is a first-in-class JAK1/JAK2 inhibitor already approved by the FDA for the treatment of polycythemia vera and myelofibrosis in adults, and for steroid-refractory acute GvHD in adult and pediatric patients ≥ 12 years.
The sNDA submission was based on data from the REACH3 study (NCT03112603). This randomized, open-label, multicenter phase III study evaluated the safety and efficacy of ruxolitinib versus best available therapy (BAT) in patients with steroid-refractory cGvHD. The trial met its primary endpoint, with a significantly higher overall response rate observed for ruxolitinib compared with BAT. In addition, treatment with ruxolitinib was associated with longer median failure-free survival, significant symptom improvement, and a higher rate of best overall response compared to BAT. The safety profile was consistent with the known safety profile of ruxolitinib. Watch our interview with Robert Zeiser on the REACH3 results, here.
The Prescription Drug User Fee Act target action date for ruxolitinib in steroid-refractory cGvHD is June 22, 2021.1
References